Search research articles
Contact Us
Filters
Showing results (221-230 of 306) with videos related to
Page
of 31
Sort By:
Blood
|
August 5, 2009
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation
Maria E Figueroa, Lucy Skrabanek, Yushan Li, et al.
Blood Advances
|
August 19, 2018
Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia
Brian Ball, Rami S Komrokji, Lionel Adès, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 12, 2002
Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia
Steven D Gore, Li-Jun Weng, William D Figg, et al.
Ecancermedicalscience
|
January 26, 2012
The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update
L R Silverman, P Fenaux, G J Mufti, et al.
British Journal of Haematology
|
July 5, 2014
Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS
Amer M Zeidan, Ju-Whei Lee, Thomas Prebet, et al.
Blood Advances
|
April 21, 2020
Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States
Amer M Zeidan, Nikolai A Podoltsev, Xiaoyi Wang, et al.
Leukemia & Lymphoma
|
May 5, 2020
Clinical outcomes and characteristics of patients with <i>TP53</i>-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience
Jan Philipp Bewersdorf, Rory M Shallis, Lohith Gowda, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 29, 2008
Reverse actin sliding triggers strong myosin binding that moves tropomyosin
T I Bekyarova, M C Reedy, B A J Baumann, et al.
British Journal of Haematology
|
September 22, 2016
Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes
Amer M Zeidan, Amy J Davidoff, Jessica B Long, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 26, 1998
A phase II "window" study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia
S D Gore, E K Rowinsky, C B Miller, et al.
Page
of 31
Search research articles
Search
Showing results (221-230 of 306) with videos related to
Sort By:
Page
of 31
Blood
|
August 5, 2009
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation
Maria E Figueroa, Lucy Skrabanek, Yushan Li, et al.
Blood Advances
|
August 19, 2018
Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia
Brian Ball, Rami S Komrokji, Lionel Adès, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 12, 2002
Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia
Steven D Gore, Li-Jun Weng, William D Figg, et al.
Ecancermedicalscience
|
January 26, 2012
The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update
L R Silverman, P Fenaux, G J Mufti, et al.
British Journal of Haematology
|
July 5, 2014
Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS
Amer M Zeidan, Ju-Whei Lee, Thomas Prebet, et al.
Blood Advances
|
April 21, 2020
Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States
Amer M Zeidan, Nikolai A Podoltsev, Xiaoyi Wang, et al.
Leukemia & Lymphoma
|
May 5, 2020
Clinical outcomes and characteristics of patients with <i>TP53</i>-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience
Jan Philipp Bewersdorf, Rory M Shallis, Lohith Gowda, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 29, 2008
Reverse actin sliding triggers strong myosin binding that moves tropomyosin
T I Bekyarova, M C Reedy, B A J Baumann, et al.
British Journal of Haematology
|
September 22, 2016
Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes
Amer M Zeidan, Amy J Davidoff, Jessica B Long, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 26, 1998
A phase II "window" study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia
S D Gore, E K Rowinsky, C B Miller, et al.
Page
of 31